First European EPO approval
Cilag, J&J's Swiss subsidiary, announces approval to market recombinant erythropoietin in Switzerland for treatment of dialysis patients who have developed anemia due to chronic renal failure. The product, initially developed by Amgen, will be marketed under the EPREX brand beginning in September. Applications for approval to treat other forms of anemia will be filed in 1989, Cilag said. A Product License Application is pending in the U.S., where Amgen's marketing partner if Ortho.
You may also be interested in...
Novavax aims to recruit 10,000 subjects in the UK, and will include a flu vaccination co-administration for some participants.
Accord has launched its first monoclonal antibody biosimilar and fourth biosimilar overall, introducing in the UK the Zercepac version of trastuzumab developed by China’s Shanghai Henlius Biotech.
Alvogen sister company Alvotech is continuing to extend its network of commercial partners by expanding its partnership with DKSH, a Swiss market expansion services group, for the commercialization of six biosimilars in Asian markets.